Industry Trends

A Harvard Business School Healthcare Alumni Association Q&A with Elaina Shekhter, EPAM’s Chief Marketing & Strategy Officer.

EVERSANA’s chief digital officer discusses recent developments in the pharma industry that are impacting its relationship with patients and new technology.

The six key design trends of 2025 redefine how healthcare brands can inspire trust and build lasting connections with their audiences.

Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five expanding therapeutic areas.

Polypharmacy, biosimilars, and GLP-1s among the evolving trends likely to play out in the pharmacy benefits space.

A look at the M&A and stock market pictures for full-year 2024—and the potential strategic implications for pharma and biotech ahead.

PwC report identifies transformative trends impacting the pharma market this year and into the future.

A surge in biotech startup out-licensing deals from the country are paving the way for increased IPO and M&A activities.

The EY executive discusses trends in this sector and what he expects to see in the coming year.

Deloitte’s US life sciences sector leader discusses the trends he believes will have the most impact in 2025.

Amid the end of a national GLP-1 shortage, the FDA will now require all compounding, distributing, or dispensing of compounded tirzepatide injections to end within 90 days.

The biosimilars market in the US is on the rise, but barriers to greater adoption remain.

Unleashed demand over the past year characterizes the M&A picture in pharma.

With the Inflation Reduction Act now in flux, how will the government and industry respond?

How alternative direct-to-consumer models are changing the landscape for patient access.

The swell of AI-powered digital platforms puts future decision-making under the spotlight.

Why investing in people and training can help drugmakers deal with six pressing challenges in particular in the year ahead.

The importance of expanding your pharma sales forecasting horizon beyond the US. Learn how to effectively navigate country-specific regulatory red flags.

Identifying the inflators and deflators, and the role all stakeholders play.

Decisions and strategies related to remote work, AI, and DE&I are especially evolving.

The CEO discusses the current state of compounding pharmacies and how it built to this point.

Growth is expected due to increased instances of chronic diseases such as cancer and Alzheimer disease.

Webinar Date/Time: Tue, Nov 19, 2024 11:00 AM EST

The Astellas chief commercial officer discusses the impact that the increase in global and local connectivity has had on commercialization, among other trends.

Webinar Date/Time: Wed, Oct 16, 2024 2:00 PM EDT

Webinar Date/Time: Wednesday, October 9th, 2024 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST

The diversification of site-of-care delivery models is accelerating rapidly, creating new go-to-market implications for drug manufacturers—but also new opportunities to drive more fundamental innovation in engagement and access strategies.

Amid shifting operating dynamics in recent years, demands for external expertise have fluctuated—leaving those arrangements that mix innovation and agility likely to win out in pharma decision-making.

A recent study by Morningstar predicts that 16 new weight-loss drugs could be on the market by 2029.

A Harvard Business School Healthcare Alumni Association Q&A with Jeremy Goldberg of Arsenal Capital Partners.